A phase 1 trial tested allogeneic induced pluripotent stem cell (iPSC)‑derived invariant natural killer T (iNKT) cells in patients with recurrent head and neck cancer. The study represents an effort to harness engineered, off‑the‑shelf cellular immunotherapies that combine iPSC scalability with innate‑like T‑cell activity to target solid tumors. Investigators reported initial safety and feasibility data from this pioneering effort, positioning iPSC‑derived immune effectors as an alternative to autologous cell therapies that require individualized manufacturing. The trial contributes early human evidence on dosing, tolerability and on‑treatment immune effects. Sponsors and translational teams highlighted logistical advantages of an allogeneic platform while noting that efficacy readouts and durability data will be required to define clinical value against existing immunotherapy options.